Non-Small Cell Lung Cancer Coverage from Every Angle

Recent News

ESMO 2019: First-Line Osimertinib in Patients With EGFR-Mutated Advanced NSCLC
WCLC 2019: Comparison of Screening Methods for Those at Risk of Lung Cancer
WCLC 2019: Blood Biomarker–Based Lung Cancer Screening
ESMO 2019: Combination Immunotherapy Versus Chemotherapy in Advanced Lung Cancer
ASTRO 2019: Adding SBRT to Pembrolizumab in Metastatic Lung Cancer
WCLC 2019: First Results Reported From the National Lung Matrix Trial
WCLC 2019: VIOLET Study Reports Benefits of VATS vs Open Lobectomy
WCLC 2019: Tumor Mutational Burden and Treatment Efficacy With Pembrolizumab
Tepotinib Granted Breakthrough Therapy Designation in Subtype of Metastatic NSCLC
WCLC 2019: LIBRETTO-001 Trial Reveals Antitumor Activity of RET Inhibitor
ASTRO 2019: Characterizing Patterns of Disease Progression in Stage III Lung Cancer
Capmatinib Granted FDA Breakthrough Therapy Designation for MET-Mutated Advanced NSCLC
Quality Care 2019: Why Do Some Patients With Lung Cancer Delay TKI Treatment?
WCLC 2019: 5-Year Overall Survival With Nivolumab From CheckMate Trials
WCLC 2019: Real-World Data on Sequential Therapy for ALK-Positive Lung Cancer
WCLC 2019: Final Data From ALUR Trial of Alectinib in Pretreated Lung Cancer
Quality Care 2019: Out-of-Pocket Costs of Oral Agents and Outcomes in Advanced Lung Cancer
Quality Care 2019: Clinical Trial Enrollment and Survival in Metastatic Lung Cancer
Detecting Brain Metastases in Patients With Lung Cancer: Comparison of Imaging Modalities
EMERGING-CTONG 1103 Trial: Neoadjuvant Erlotinib in EGFR-Mutant Lung Cancer
Entrectinib Approved by FDA for ROS1-Positive NSCLC
Two-Drug Combination Targets Resistance in Cancer
Early Results With Dual Inhibition of VEGFR2 and PD-1 in Advanced Lung Cancer
Can Lower Radiation Doses Reduce Damage to Immune System and Improve Outcomes in NSCLC?
Pemetrexed/Carboplatin/Gefitinib: New Standard of Care for Untreated EGFR-Mutant Lung Cancer?
A Risk Prediction Model For Patients With Lung Nodules
Adjuvant Therapy for Completely Resected Advanced Nonsquamous NSCLC
RET Inhibitor Shows Activity in Select Patients With Lung Cancer in ARROW Trial
FDA Approves Bevacizumab Biosimilar in Nonsquamous NSCLC
ASCO 2019: Dual EGFR and VEGFR Blockade in Metastatic Lung Cancer
ASCO 2019: Interim Results With Neoadjuvant Atezolizumab in Resectable Lung Cancer
ASCO 2019: Proton Therapy Versus Conventional Photon Therapy in Locally Advanced Cancer
ASCO 2019: Comparing Maintenance Therapies for Nonsquamous Lung Cancer
ASCO 2019: Neoadjuvant Combination Checkpoint Blockade in Early-Stage NSCLC
ASCO 2019: Long-Term Survival With Pembrolizumab for Advanced NSCLC
ASCO 2019: Expanding Traditional Clinical Trial Eligibility in NSCLC
Predicting the Course of Lung Cancer in Situ
Pooled Analysis of Use of Entrectinib in ROS1-Positive Lung Cancer
Lung Cancer Organizations Launch Collaborative Foundation for Lung Cancer Community
ELCC 2019: Does Age Affect Toxicity in Immunotherapy-Treated Patients With NSCLC?
ELCC 2019: Patient-Reported Outcomes With Durvalumab in NSCLC
Can Clinical Use of Capsaicin Slow the Spread of Lung Adenocarcinoma?
ELCC 2019: First-Line Treatment With Osimertinib in Advanced EGFR -Mutant NSCLC
ELCC 2019: Larotrectinib in TRK Fusion–Positive Lung Cancer
AACR 2019: Savolitinib Plus Osimertinib in EGFR -Mutant, MET-Amplified NSCLC
ELCC 2019: Pembrolizumab Monotherapy in Elderly Patients With Advanced NSCLC

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.